Association of Structural and Functional Cardiac Changes With Transcatheter Aortic Valve Replacement Outcomes in Patients With Aortic Stenosis

Abstract

IMPORTANCE Severe aortic stenosis causes pressure overload of the left ventricle, resulting in progressive cardiac dysfunction that can extend beyond the left ventricle. A staging system for aortic stenosis has been recently proposed that quantifies the extent of structural and functional cardiac changes in aortic stenosis.OBJECTIVES To confirm the reproducibility of a proposed staging system and expand the study findings by performing a survival analysis and to evaluate the association of aortic stenosis staging with both cardiac and noncardiac post-transcatheter aortic valve replacement (TAVR) readmissions. DESIGN, SETTING, AND PARTICIPANTSA cohort analysis was conducted involving patients with severe aortic stenosis who underwent TAVR at the University of Pittsburgh Medical Center between July 1, 2011, and January 31, 2017. Patients who had undergone TAVR for valve-in-valve procedures and had an incomplete or unavailable baseline echocardiogram study for review were excluded. Clinical, laboratorial, and procedural data were collected from the Society of Thoracic Surgeons database and augmented by electronic medical record review.EXPOSURES The aortic stenosis staging system is based on echocardiographic markers of abnormal cardiac function. The stages are as follows: stage 1 (left ventricle changes − increased left ventricular mass index; early mitral inflow to early diastolic mitral annulus velocity (E/e′) >14; and left ventricular ejection fraction <50%), stage 2 (left atrial or mitral changes − left atrial volume index >34 mL/m 2 ; moderate to severe mitral regurgitation; and atrial fibrillation), stage 3 (pulmonary artery or tricuspid changes − pulmonary artery systolic pressure Ն60 mm Hg; moderate to severe tricuspid regurgitation), and stage 4 (right ventricle changes − moderate to severe right ventricle dysfunction). MAIN OUTCOMES AND MEASURESPrimary outcome was post-TAVR all-cause mortality. Secondary outcomes were composite outcomes of all-cause mortality and post-TAVR all-cause and cardiac-cause readmissions.RESULTS A total of 689 consecutive patients (351 [50.9%] were male, with a mean [SD] age of 82.4 [7.6] years) were included. The prevalence of stage 1 was 13%; stage 2, 62%; stage 3, 21%; and stage 4, 4%. Patients with higher staging had a greater burden of comorbidities as captured by the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM). Despite adjustment for STS-PROM, a graded association was found between aortic stenosis staging and all-cause mortality (hazard ratio [HR] stage 2 vs stage 1: 1.37 [95% CI, 0.81-2.31; P = .25]; stage 3 vs stage 1: 2.24 [95% CI, 1.28-3.92; P = .005]; and stage 4 vs stage 1: 2.83 [95% CI, 1.39-5.76; P = .004]). Stage 3 patients had higher post-TAVR readmission rates for both cardiac (HR, 1.84; 95% CI, 1.13-3.00; P = .01) and noncardiac causes. CONCLUSIONS AND RELEVANCEAortic stenosis staging appears to show a strong graded association between the extent of cardiac changes and post-TAVR all-cause mortality; such staging may improve patient care, ...

Impact of diastolic dysfunction on long‐term mortality and quality of life after transcatheter aortic valve replacement

“…One‐year mortality was 4.4% in Stage 0, 9.2% in Stage 1, 14.4% in Stage 2, 21.3% in Stage 3, and 24.5% in Stage 4 ( p < .001) . These findings have been reproduced in a real‐world cohort of patients treated with TAVR as well . Although not identical, the current ASE criteria for DD grading incorporate many of the defining features of the staging system such as E/e' > 14 (Stage 1), enlarged left atrium (Stage 2), and the presence of systolic pulmonary hypertension or moderate to severe TR (Stage 3).…”

Multimodality Imaging for Discordant Low-Gradient Aortic Stenosis: Assessing the Valve and the Myocardium

“…This staging system relies on the concept that increased LV afterload induced by the stenotic aortic valve leads to progressive and sequential damage to heart chambers in an upstream fashion. Even though it does not discriminate causality (e.g., a Stage 3 significant pulmonary hypertension can be secondary either to a very severe AS or to chronic obstructive pulmonary disease), it has proven to be a powerful predictor of mortality not only after AVR ( 6 , 102 ) but also in symptomatic ( 90 ) and asymptomatic ( 5 ) AS patients. The latter used a modified schema suggested by Tastet et al that incorporates some valuable changes, such as raise the severity cut-point of LVEF from 50% to 60% and incorporate GLS (<15%) as a mean to increase detection of subclinical LV dysfunction.…”

Natural Foods and Indian herbs of cardiovascular interest

“…Complications of heart disease [14][15][16][17][18][19][20][21][22][23][24][25] Heart failure One of the most common complications of heart disease, heart failure occurs when heart can't pump enough blood to meet body's needs. Heart failure can result from many forms of heart disease, including heart defects, cardiovascular disease, valvular heart disease, heart infections or cardiomyopathy.…”